Private Equity

With its new HAE drug EKTERLY® smashing revenue forecasts, KalVista heads to key conferences where investors will scrutinize its path to profitability.

U.S. Energy Corp. unveils an ambitious plan to merge helium, oil, and carbon capture, but can this small-cap company deliver on its big promises?

The fashion giant's revenue grew 11% in 2025, but net income fell sharply due to acquisition costs, tariffs, and a murky outlook for 2026.

With the appointment of TechTarget co-founder Don Hawk, Life Science Connect is set to import a proven B2B intent data playbook into the life sciences.

The private aviation operator has secured the FAA Diamond Award, signaling a new benchmark in aircraft safety and technician training for the industry.

Fresh off record profits, World Gym details its strategy for global growth, betting on AI health platforms and high-margin services to reshape the industry.

The Swedish health firm reports a 51% revenue surge and record profits, fueled by a string of strategic acquisitions aimed at dominating the Americas.

Insurance giant Kuvare Holdings fires back at inaccurate reports, clarifying its independent oversight in a complex asset management deal with Blue Owl.

Archrock crushes profit estimates and hikes its dividend, signaling strong confidence as it positions to power the soaring energy demands of LNG and AI.

The biotech firm secures major funding to push its promising head and neck cancer drug, ficerafusp alfa, toward regulatory approval and commercial launch.

The life sciences giant's significant dividend hike underscores its robust financial health and commitment to growth, even as it pursues major acquisitions.

Amid market headwinds, Knightvest executed $1.15B in deals and fortified its finances, signaling strong confidence in a 2026 multifamily recovery.

Amid market volatility, Houston's Marble Capital hires Doug Goff to lead a new open-end fund, doubling down on its Sunbelt multifamily strategy.

Dallas-based Huitt-Zollars acquires San Diego's Vasquez Marshall Architects, a strategic move to dominate the lucrative federal design market in the region.

A planned reverse merger for promising vaccine developer SVF Vaccines has collapsed after Nasdaq rejected the deal, leaving its lead investor scrambling.

A landmark private equity deal sees Specialty Fenestration Group sold after explosive growth, signaling a boom in the high-security solutions market.

The tech firm announced progress on a major health contract, but with its stock near all-time lows, can this deal deliver a much-needed turnaround?

The legacy brand blends heritage, market strategy, and conservation with its new 8-year bourbon, inspired by 19th-century decanters and now available nationwide.

Dupixent's landmark FDA approval offers a new, surgery-sparing option for a debilitating sinus disease, but questions of access and cost remain.

The national safety giant's latest Houston acquisition strengthens its market hold, integrates deep expertise, and expands its all-in-one service model.